不断演变的分类系统对弥漫性胶质瘤数据库的影响:悉尼脑肿瘤库的经验
该研究评估了不断演变的肿瘤分类系统对机构脑肿瘤库及多个多机构胶质瘤数据库的影响。研究从悉尼脑肿瘤库(1993-2025)获取临床病理和分子数据,并从Rembrandt、Gravendeel、CGGA和TCGA数据集获取可用数据,将所有病例按WHO中枢神经系统肿瘤分类第5版重新分类。结果显示,2016年WHO分类修订第四版之前诊断的病例中37%至100%需要额外分子检测才能准确诊断和分级;而2016年分类后建立的数据集中多数病例(61%至97%)符合WHO 2021分类标准。
要点
- 2016年前诊断的胶质瘤病例中37%至100%需补充分子检测以准确诊断分级。
- 2016年后建立的数据集中61%至97%的病例符合WHO 2021分类标准。
- 55岁以下高级别胶质瘤和IDH突变组织学2/3级胶质瘤持续不满足2021标准。
核心结论
- 不断演变的肿瘤分类系统要求定期审查和重新分类脑肿瘤数据集,以确保脑癌研究的准确性和公平性。
- 重新分类后的数据集已提供给全球神经肿瘤研究者使用。
研究设计与样本
- 研究从悉尼脑肿瘤库登记处(1993-2025)获取临床病理数据包括分子谱。
- 从Rembrandt、Gravendeel数据集、中国胶质瘤基因组图谱(CGGA)和癌症基因组图谱(TCGA)获取可用的临床病理和分子分类数据。
- 所有病例按WHO中枢神经系统肿瘤分类第5版重新分类。
主要发现
- 在2016年WHO分类(修订第四版)之前诊断的病例中,37%至100%需要额外分子检测才能准确诊断和分级。
- 在2016年分类之后建立的数据集中,多数病例(61%至97%)符合WHO 2021分类标准。
- 持续不满足2021要求的两个队列为55岁以下患者的高级别胶质瘤和IDH突变组织学2/3级胶质瘤。
临床怎么用
- 神经肿瘤研究中使用历史数据集时应按最新WHO分类重新分类,必要时补充分子检测。
- 对55岁以下高级别胶质瘤和IDH突变组织学2/3级胶质瘤需特别关注分类标准更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain tumour classification is a rapidly evolving field, with diagnostic evaluation integrating the latest in molecular testing techniques. As data in brain tumour registries and repositories are collected in real time, neuro-oncology researchers face clear challenges when analysing tumour cohorts diagnosed according to differing standards over time. This study aims to evaluate the impact of an evolving tumour classification system on both our institutional registry and widely used multi-institutional repositories in glioma translational research. METHODS: Clinicopathological data, including molecular profiles, were obtained from the Sydney Brain Tumour Bank registry (1993-2025). We sourced available clinicopathological and molecular classification data from the Rembrandt and Gravendeel datasets, the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA). All cases were reclassified according to the WHO Classification of Tumours of the Central Nervous System (5th edition). RESULTS: Between 37% and 100% of cases diagnosed prior to the 2016 WHO Classification (revised fourth edition) require additional molecular testing for accurate diagnosis and grading. In contrast, the majority of cases in datasets established after the 2016 Classification met the WHO 2021 Classification criteria (61% to 97%). Two cohorts that consistently failed to meet 2021 requirements over time were high-grade gliomas in patients under 55 years and histological grade 2/3 IDH-mutant gliomas. CONCLUSION: An evolving tumour classification system necessitates regular review and reclassification of brain tumour datasets to ensure that brain cancer research is accurate and equitable. The reclassified datasets are provided for use by neuro-oncology researchers worldwide.
引用
- Satgunaseelan L, Xian E, Madani D, et al. Impact of an evolving classification system on diffuse glioma repositories: experience from the Sydney brain tumour bank. J Neurooncol. 2026. PMID: 41712020. doi:10.1007/s11060-026-05470-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。